Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 54, Issue 4, Pages 531-545Publisher
ELSEVIER
DOI: 10.1016/S0169-409X(02)00026-1
Keywords
poly(ethylene glycol); monoclonal antibody; Fab'; single chain antibodies; antibody fragment; pharmacokinetics
Categories
Ask authors/readers for more resources
The use of covalent attachment of poly(ethylene glycol) to various different proteins in order to modify their function has been reported over many years. One class of protein that this technology has more recently been applied to is antibodies and antibody fragments. PEG has been predominantly used to reduce the immunogenicity and increase the circulating half-lives of antibodies. It may also have a beneficial effect on the use of antibodies in certain clinical settings such as tumour targeting. This review describes previously reported experience with PEGylated antibodies and antibody fragments, and where these types of molecules may find clinical usefulness in the future. (C) 2002 Elsevier Science B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available